-0.04 (-1.96%)
Dilution Risk
25%R&D Expenses
3.20 M
Operating CF
-4.57 M
Total Assets
27.30 M
Total Liabilities
9.67 M
Equity
17.63 M
D/E Ratio
12,345
Cash Position
24.53 M
Monthly Burn
1.52 M
Runway
13.6 mo
Burn Trend
StableSEC Filing
May 14, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Peptides | Nervous System | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Peptides | Nervous System | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Peptides | Nervous System |
Dated clinical, regulatory & corporate events for AgeX Therapeutics, Inc.
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-09-30 | SER-155 | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-09-30 | SER-155 | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-09-30 | SER-155 | Phase 2 data readout | Phase 2 | — | – | – | – |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SER-252 Small molecule | PARKINSON DISEASE (Disorder) | Phase 1 | NCT07422675 | 5% | $56M | RECRUITING | 40 | STALLED | D (23) | Jan 1, 2027 | MODERATE_RISK | LOW May 24, 2026 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Serina Therapeutics will participate in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. The company aims to showcase its proprietary POZ Platform™, which enhances drug delivery and addresses pharmacokinetic limitations. Management will hold one-on-one investor meetings, emphasizing their commitment to advancing their innovative drug candidates.
Read more →Serina Therapeutics has appointed Farrell Simon, Pharm. D., to its Board of Directors. Dr. Simon brings extensive experience from Trevi Therapeutics and Pfizer, which will aid Serina in advancing its SER-252 program. The company aims to leverage its POZ Platform™ technology to enhance drug delivery for neurological diseases.
Read more →Serina Therapeutics has completed sentinel dosing in Cohort 1 of its Phase 1b trial for SER-252, aimed at treating advanced Parkinson's disease. The independent Safety Monitoring Committee has recommended continuing dosing based on initial safety observations. The company anticipates completing enrollment and dosing ahead of the previously set timeline of Q3 2026.
Read more →Serina Therapeutics has reported its financial results for Q1 2026 and provided updates on its business operations. The company has initiated a Phase 1b registrational clinical study for SER-252, targeting advanced Parkinson's disease, with data from the study expected in early 2027. Additionally, Serina has successfully closed a $21.2 million private placement to support its ongoing development. However, the company also reported an increase in net loss and operating expenses compared to the previous year.
Read more →Serina Therapeutics has received acceptance from NYSE American for its compliance plan to meet listing standards. The company aims to regain compliance by July 2027 while continuing its SER-252 clinical program. However, it faces challenges due to previous financial losses and low stockholders' equity.
Read more →Serina Therapeutics reported its financial results for 2025, highlighting significant advancements including FDA clearance for SER-252 and the initiation of its Phase 1b trial for Parkinson's disease. The company secured up to $30 million in financing, enhancing its clinical and financial position. However, it also reported an increased net loss and rising operating expenses.
Read more →Serina Therapeutics will present at the 38th Annual Roth Conference on March 24, 2026. CEO Steve Ledger will discuss the company's proprietary POZ Platform™ technology and its applications in treating neurological diseases. The presentation will be available via live webcast and archived for 90 days. The POZ technology aims to enhance drug delivery and efficacy.
Read more →Serina Therapeutics has announced a private placement that will raise up to $30 million to support the registrational trial of its drug SER-252 for advanced Parkinson's disease. The funding includes an initial tranche of $15 million expected to close on March 20, 2026, and a second tranche of the same amount anticipated shortly after. The financing structure is designed to align capital deployment with upcoming clinical milestones, including the ongoing registrational study aimed at providing a new treatment option for patients inadequately served by current therapies. Serina's approach is bolstered by a favorable regulatory pathway confirmed by recent FDA feedback.
Read more →Serina Therapeutics has initiated dosing in its Phase 1b registrational trial for SER-252, targeting advanced Parkinson's disease. The trial aims to assess the safety and efficacy of SER-252, which utilizes the company's proprietary POZ Platform™. With FDA alignment on its regulatory pathway, Serina is positioned to generate critical clinical data.
Read more →Serina Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Steven Ledger, will present at a webinar titled 'Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences' on February 4, 2026. The event will allow participants to ask questions directly to the CEO. Registration is available through Tribe Public's website.
Read more →Serina Therapeutics has received FDA clearance for its IND application for SER-252, an investigational therapy aimed at treating advanced Parkinson's disease. This clearance enables the company to start regulatory activities and initiate a Phase 1b clinical study. The CEO emphasized the importance of this milestone and the potential of SER-252 to meet significant medical needs.
Read more →Serina Therapeutics has submitted a complete response to the FDA regarding the clinical hold on its SER-252 program for advanced Parkinson's disease. The FDA's hold was due to requests for additional information on a formulation excipient. The company is actively preparing for a Phase 1b study, aiming for the first patient to be enrolled in early 2026, pending FDA feedback.
Read more →Serina Therapeutics has submitted a complete response to the FDA's clinical hold letter regarding its lead program, SER-252, for advanced Parkinson's disease. The move addresses the FDA's requests related to the formulation excipient trehalose and includes a detailed data package. The company continues its global site start-up activities, aiming for first patient enrollment in Q1 2026, pending FDA feedback. CEO Steve Ledger expressed optimism around their submission and the potential progression of the trial.
Read more →Serina Therapeutics reported its financial results for Q3 2025, highlighting key achievements including FDA support for advancing SER-252 under a 505(b)(2) NDA pathway for advanced Parkinson's disease. The company is addressing a clinical hold on SER-252 and expects formal communication from the FDA soon. Additionally, Serina secured up to $20 million in funding and is making progress on its SER-270 program for tardive dyskinesia. Efforts to improve stakeholder communications were also announced as part of its corporate strategy.
Read more →Serina Therapeutics has announced that the FDA has placed a clinical hold on their SER-252 program due to the need for additional information regarding a formulation component. This feedback does not relate to the drug's active substance or its proposed mechanism of action. The company intends to address the FDA's requests promptly and continues to believe in the potential of SER-252 for treating advanced Parkinson's disease. Despite the hold, Serina is committed to advancing the program and aims to provide an update once they align with the FDA on next steps.
Read more →Serina Therapeutics has secured the first $5 million of a financing agreement, enabling it to advance the registrational trial of SER-252 for advanced Parkinson's disease. The funding is part of a larger agreement worth up to $20 million that is contingent on meeting development milestones. The company has submitted an Investigational New Drug application to the FDA and received necessary ethical approvals in Australia, with plans to initiate the global trial in Q4 2025. SER-252 aims to provide continuous dopaminergic stimulation via subcutaneous injection, improving patient outcomes in advanced Parkinson's treatment.
Read more →Serina Therapeutics has announced the securing of up to $20 million in financing to advance the registrational trial of their investigational drug SER-252 for advanced Parkinson's disease. The funding, led by Board Director Greg Bailey, will be drawn through a multi-tranche, unsecured convertible note. This financing plan allows Serina to proceed in accordance with clinical milestones, maintaining the flexibility to seek additional funding options. The registrational trial is expected to begin patient dosing in Q4 2025, with potential global implications for treatment efficacy in advanced Parkinson's patients.
Read more →Serina Therapeutics recently announced its financial results for the second quarter of 2025, highlighting key developments in its drug pipeline. The company is progressing with SER-252, aimed at treating advanced Parkinson's disease, and SER-270, targeting tardive dyskinesia. Despite a reported net loss of $6.4 million, Serina's advancements reflect the potential of its proprietary POZ platform in creating long-acting therapies. The company secured $5 million in funding to support ongoing development activities.
Read more →Serina Therapeutics has announced the advancement of its investigational drug POZ-VMAT2i for treating tardive dyskinesia (TD), emphasizing its potential to meet the needs of underserved patients facing adherence challenges. The compound is a once-weekly injectable vesicular monoamine transporter 2 inhibitor that may provide significant benefits over existing oral medications. Additionally, Serina aims to explore the use of POZ-VMAT2i for chorea associated with Huntington's disease, indicating the company's commitment to addressing various neurological disorders. This development reflects a strong opportunity for growth in the TD market, which is projected to expand significantly in the coming years.
Read more →Serina Therapeutics has announced that the date for its 2025 annual stockholders meeting is set for November 7, 2025. The notice includes details for stockholders on submitting proposals and nominations for consideration, with specific deadlines outlined. This change is significant as it deviates from the usual scheduling by more than 30 days. Serina, a biopharma company focused on developing treatments for neurological diseases, will provide further details in its definitive proxy statement.
Read more →Serina Therapeutics has reported its financial results for Q1 2025, highlighting significant advancements in its clinical pipeline, particularly for SER-252, an investigational therapy for advanced Parkinson's disease expected to begin clinical trials later this year. The company secured $15 million in funding, enhancing its financial stability, and appointed two new experienced members to its Board of Directors. Despite reporting a net loss, the company emphasized its commitment to expanding its innovative POZ Platform across various therapeutic modalities. New data presented at a recent summit showed promising results for their lipid nanoparticle formulations, potentially enhancing gene therapy efficacy.
Read more →At the 4th LNP Formulation and Process Development Summit in Boston, Serina Therapeutics presented a non-confidential overview of their innovative use of poly(2-oxazoline) (POZ) as a replacement for PEG-lipids in lipid nanoparticle formulations. This shift aims to minimize immune responses noted in existing mRNA vaccine technologies. The presentation also detailed the risks associated with forward-looking statements, particularly surrounding clinical trial results and regulatory approvals.
Read more →Serina Therapeutics has announced the completion of a $5 million financing round to further develop SER-252, its lead candidate for advanced Parkinson's disease. The funds will support the preparation for a Phase 1 clinical trial scheduled for the fourth quarter of 2025. CEO Steve Ledger highlighted the financing as a sign of strategic investor confidence in the drug's potential, which is designed to provide continuous dopaminergic stimulation. The company is employing its proprietary POZ Platform technology to optimize drug delivery and improve patient outcomes.
Read more →Serina Therapeutics, a clinical-stage biotechnology company, announced its CEO Steve Ledger will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, in Las Vegas. The company is focusing on its proprietary POZ Platform designed to optimize drug development for neurological diseases and other indications. Attendees will have access to a live webcast, and a replay will be available for 90 days post-event. Cautionary statements highlight the substantial risks and uncertainties associated with the company's forward-looking objectives, including regulatory approval and clinical trial outcomes.
Read more →Serina Therapeutics will present new findings on its proprietary POZ-lipid technology at the ACS Spring 2025 Meeting. The data indicates that the POZ-lipid does not trigger an immune response, contrasting with conventional PEG-lipids that can provoke adverse reactions in patients. This breakthrough could lead to improved safety profiles for RNA-based therapies. The company aims to advance its drug delivery platform for various therapeutic applications.
Read more →Serina Therapeutics reported its financial results for the full year 2024, highlighting a significant drop in revenues to $56 thousand from $3.2 million in 2023. The company has made strategic moves, including a $10 million equity financing and the elimination of $11.2 million in debt through the sale of its UniverXome subsidiary. Serina is advancing SER-252 into a Phase 1 clinical trial for advanced Parkinson's patients and has strengthened its Board of Directors with experienced new members. Despite a net loss of $11.1 million for 2024, the company's innovative efforts with its POZ Platform signal potential for future growth.
Read more →Serina Therapeutics has announced the closing of a $5 million tranche of funding to advance its investigational drug SER-252 into a Phase 1 clinical trial for advanced Parkinson's disease. The financing comes from strategic shareholder JuvVentures and reinforces the company's cash position. SER-252 aims to utilize Serina's proprietary POZ technology for continuous dopaminergic stimulation, potentially improving patient outcomes. The Phase 1 trial is expected to commence in the latter half of 2025.
Read more →Serina Therapeutics announced a $10 million financing agreement with JuvVentures to support the advancement of its lead candidate, SER-252, into a Phase 1 clinical trial targeting advanced Parkinson's disease patients. The financing involves issuing one million shares of common stock at a premium price. The clinical trial is expected to initiate in the second half of 2025. Moreover, SER-252 utilizes Serina's proprietary POZ platform technology, which could improve patient's quality of life by providing continuous dopaminergic stimulation through an easy-to-administer subcutaneous injection.
Read more →Serina Therapeutics, a clinical-stage biotechnology firm, reported its financial results for Q3 2024, detailing continued investments despite rising expenses. While revenues remain low and derived solely from grants, the company's lead candidate SER-252, targeting Parkinson's disease, shows promise as it advances toward clinical testing. However, the report raises concerns about the company's financial sustainability due to increased operational costs and diminished net income. The future funding outlook remains uncertain as the company assesses its cash flow needs.
Read more →Serina Therapeutics announced that its Interim CEO, Steve Ledger, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024. The conference will feature a live webcast of the presentation, which can be accessed on Serina's website. The company is known for its proprietary POZ Platform drug delivery technology aimed at improving treatments for neurological diseases and other indications. Serina is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.
Read more →Serina Therapeutics reported its financial results for Q2 2024, revealing a partnership with Enable Injections to develop SER-252 for Parkinson's disease. The company also presented promising data on its POZ-lipid technology that may enhance the safety of mRNA-LNP formulations. However, financial concerns arise as the company indicated substantial doubt about its ability to continue as a going concern in light of its cash flow projections. Additionally, net income decreased from the previous year, impacting the company’s financial outlook.
Read more →Serina Therapeutics has appointed Dr. Srini Tenjarla as the new Senior Vice President of CMC and Formulation. He has over 20 years of experience in pharmaceutical development, previously holding leadership roles at Takeda Pharmaceuticals and Shire Pharmaceuticals. His expertise in formulation development and strategic leadership is anticipated to significantly benefit Serina's pipeline and improve its drug delivery technology. Dr. Tenjarla expressed enthusiasm about contributing to the company's innovative work in drug development.
Read more →Serina Therapeutics has released its first quarter 2024 financial results, reporting a net loss of $9.4 million primarily due to the recent merger with AgeX Therapeutics and increased operating costs. The company is advancing its lead drug candidate, SER-252, for Parkinson's Disease, with plans to initiate clinical trials in 2025. Additionally, Serina's management has strengthened with the appointment of Dr. Simba Gill as Executive Chairman, aiming to navigate the next phase of growth amidst financial challenges.
Read more →Serina Therapeutics has appointed Dr. Simba Gill as Executive Chairman, who brings over thirty-five years of experience in the biotechnology sector. His leadership is expected to guide Serina in advancing its proprietary POZ PlatformTM, which aims to enhance drug delivery across multiple modalities. Dr. Gill has a strong background in building companies and overseeing drug development, which positions him as a vital asset for the company's upcoming growth and strategic initiatives. The company focuses on improving therapeutics for various neurological diseases and pain management.
Read more →Serina Therapeutics has successfully completed its merger with AgeX Therapeutics, enabling it to operate under the NYSE ticker symbol 'SER' starting March 27, 2024. The merger allows Serina to advance its lead candidate, SER-252, targeting Parkinson's Disease with anticipated preclinical studies concluding in Q4 2024. A Phase I clinical trial is planned for 2025 following an IND submission to the FDA, marking a significant step in Serina's development of treatments for neurological conditions.
Read more →AgeX Therapeutics has announced its fourth quarter and annual financial results for 2023, reporting a significant increase in net loss from the previous year. The company recently secured an additional $4.4 million line of credit as it moves forward with the merger with Serina Therapeutics. Despite these efforts, AgeX expressed concerns regarding its financial viability and ability to meet upcoming obligations, as operating expenses have substantially increased. As of December 31, 2023, AgeX's future remains uncertain amidst rising debts and losses.
Read more →Serina Therapeutics, Inc. announced a licensing agreement with Pfizer Inc. for its proprietary POZ polymer technology, intended for use in RNA-based therapeutics. This non-exclusive agreement marks a key milestone for Serina as it aims to improve drug delivery systems. The POZ Platform™ is designed to address limitations of existing polymers and enhance the control over drug loading and release rates. The collaboration is expected to advance research and development activities in the field of neurological diseases and pain management.
Read more →AgeX Therapeutics has reported its financial results for the third quarter of 2023, highlighting a net loss of $5.4 million and increased operating expenses of $2.4 million. The company successfully eliminated $36 million in debt through the issuance of preferred stock, which is now classified as permanent equity. However, AgeX faces substantial doubts regarding its cash flow and ability to continue operating without additional financing. The results reflect ongoing challenges as the company pursues its developmental goals in aging therapeutics.
Read more →Serina Therapeutics has entered into a merger agreement with AgeX Therapeutics, forming a new company focused on advancing Serina's therapeutic pipeline, including the lead candidate SER-252 for advanced Parkinson's disease. The merger is structured as an all-stock transaction and will result in Serina maintaining its name, with a projected close in Q1 2024. The combined entity plans to explore greater collaborations using Serina's proprietary delivery technology, the POZ Platform, across various therapeutic areas while aiming for significant advancements in CNS treatment options.
Read more →AgeX Therapeutics reported its financial results for the second quarter of 2023, revealing a net loss of $2.7 million. The company has faced financial challenges, highlighting concerns about its ability to continue operations. AgeX has engaged in a debt exchange with Juvenescence Limited, reducing its indebtedness significantly. Additionally, there have been leadership changes within the company, with a new interim CEO appointed amid efforts to stabilize the organization.
Read more →AgeX Therapeutics completed a debt exchange, issuing $36 million of newly authorized Preferred Stock to Juvenescence Limited in exchange for the cancellation of loans. This exchange has bolstered AgeX's stockholder equity to approximately $16 million, allowing them to meet the NYSE American's listing requirements. The move has led to the withdrawal of a delisting determination by the NYSE and cancellation of a related hearing. However, certain restrictions remain on issuing shares of common stock upon conversion of the new Preferred Stock.
Read more →AgeX Therapeutics has announced a $36 million debt exchange agreement with Juvenescence Limited, involving the issuance of preferred stock to improve financial standing and meet NYSE listing requirements. This exchange is projected to raise AgeX's stockholders' equity significantly, correcting a previous deficit. However, compliance and the full realization of this financial improvement are contingent upon NYSE's approval and may be affected by potential future losses.
Read more →AgeX Therapeutics announced that it will appeal a determination by the NYSE American to delist its common stock due to non-compliance with stockholders' equity requirements. The company reported having insufficient stockholders' equity and significant losses over the past fiscal years. AgeX intends to request a hearing which could temporarily halt the delisting process. The future of AgeX's listing remains uncertain as it seeks to address these financial challenges.
Read more →AgeX Therapeutics reported its financial results for the first quarter of 2023, showing an increase in revenues but also a higher net loss compared to the previous year. The company is facing significant financial challenges, including substantial debt and concerns about its ongoing viability. Despite a small increase in revenue, the overall financial outlook remains negative, prompting worry about AgeX's ability to meet its obligations in the near future. Additionally, operational costs have risen, largely due to expenses associated with a potential merger with Serina Therapeutics.
Read more →AgeX Therapeutics has received a deficiency letter from the NYSE American indicating it does not meet the stockholders' equity requirements. The company currently has stockholders equity below $2 million and has reported significant losses over the last few fiscal years. If AgeX fails to address these deficiencies and comply with the exchange's standards by May 17, 2023, it may face delisting proceedings. In such an event, AgeX plans to have its common stock quoted on an alternative electronic interdealer quotation system.
Read more →AgeX Therapeutics reported its financial results for the fourth quarter and full year of 2022, showing a significant decline in revenues and an increase in net losses compared to 2021. Total revenues dropped to $34,000 from $144,000 the previous year, while net losses rose to $10.5 million. The company highlighted concerns regarding its ability to continue operating as a viable entity due to cash flow issues and substantial debt obligations. These financial results have raised substantial doubt about AgeX's capacity to fulfill future financial commitments.
Read more →AGEX THERAPEUTICS RECEIVES EXTENSION OF TIME TO ATTAIN COMPLIANCE WITH STOCK EXCHANGE CONTINUED LISTING REQUIREMENTS ALAMEDA, Calif.-(BUSINESS WIRE)-November 25, 2022 - AgeX Therapeutics , Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for
Read more →Therapeutics Reports Third Quarter 2022 Financial Results Calif.-(BUSINESS WIRE)-November 10, 2022-AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating result
Read more →Therapeutics Reports Second Quarter 2022 Financial Results Calif.-(BUSINESS WIRE)-August 12, 2022-AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results
Read more →Joanne Hackett Appointed Chairperson of AgeX Board of Directors Calif.-(BUSINESS WIRE)-May 18, 2022-AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett ha
Read more →Therapeutics Reports First Quarter 2022 Financial Results Calif.-(BUSINESS WIRE)-May 13, 2022-AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for
Read more →Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results Signed research collaboration with University of California, Irvine, on research program for exosome-based therapies for certain brain disorders Licensee ImStem Biotechnology announced first U.S. multiple
Read more →Therapeutics Reports Third Quarter 2021 Financial Results Calif.-(BUSINESS WIRE)-November 12, 2021-AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating result
Read more →Therapeutics Reports Second Quarter 2021 Financial Results Calif.-(BUSINESS WIRE)-August 13, 2021-AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results
Read more →AgeX Therapeutics and LyGenesis Terminate Merger Negotiations ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--July 23, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis,
Read more →Therapeutics Reports First Quarter 2021 Financial Results and Sponsored research at The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity Announced Preprint Article Relating to
Read more →Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update Sponsored research at The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity S
Read more →Therapeutics and LyGenesis to Negotiate Merger Agreement would create a clinical-stage cell therapy company CA & PITTSBURGH, PA - March 2, 2021 - AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell rege
Read more →AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Sublicensed stem cell line ESI-053 to ImStem Biotechnology for development of cell therapy candidate IMS001 for COVID-19 and acute respiratory distress syndrome from other causes. Expand
Read more →AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update ALAMEDA, Calif.--(BUSINESS WIRE)--August 14, 2020--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration,
Read more →AgeX Therapeutics Receives Stock Exchange Deficiency Letter ALAMEDA, Calif.--(BUSINESS WIRE)--June 5, 2020--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 202
Read more →AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update ALAMEDA, Calif.--(BUSINESS WIRE)--May 14, 2020--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, rep
Read more →AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update Entered research collaboration with Japanese biopharma company to generate hypoimmunogenic cells Formed collaboration with UC Irvine on neural stem cell research program for
Read more →AgeX Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update Advanced GMP-compliant manufacturing capability Published two peer-reviewed scientific papers Included in MIT Technology Review Special Issue on Longevity Presented at industry and inv
Read more →AgeX Therapeutics, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update Moves into new San Francisco Bay Area R&D facility, comprising approximately 15,700-square-feet of office and lab space, including cGMP-capable manufacturing suite. Strengthens le
Read more →Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update Published data in peer-reviewed scientific journal to advance potential cell therapy AgeX-BAT1 for Type II Diabetes and obesity Received $4.5 million from the exercise of warrants in March
Read more →Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update 2018 with triad of innovative cell therapy technologies: UniverCyte for immune tolerance, PureStem for cell derivation and manufacturing, and HyStem to generate any human cell
Read more →Therapeutics, Inc. Shares Commence Trading on the NYSE American Common Stock Listed Under Symbol "AGE" ALAMEDA, Calif.--(BUSINESS WIRE)--November 29, 2018--AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization o
Read more →